Navigation Links
Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO
Date:9/29/2009

PLEASANTON, Calif., Sept. 29 /PRNewswire/ -- Zeltiq Aesthetics, a science-based medical device company dedicated to the development of non-invasive procedures for the reduction of unwanted fat tissue, has announced the appointment of Gordie Nye as its new CEO. Mr. Nye succeeds Mitch Levinson, the founder of Zeltiq Aesthetics, who served as President since September 2005, and as Chief Executive Officer and a member of the Board of Directors since 2006. Mr. Levinson will continue as a key member of the senior executive team.

Gordie Nye brings over 25 years of senior management and operational expertise to Zeltiq Aesthetics. During his career, Mr. Nye has demonstrated outstanding leadership skills, and has both deep life sciences and consumer marketing experience.

In 2003, Mr. Nye joined Prism VentureWorks as a General Partner in its life sciences investment team where he focused on medical devices. During this time, he served on the boards of several Prism portfolio companies and will remain active as a Director of certain select Prism companies.

"We are very excited to have Gordie on board signaling the transition of Zeltiq to a commercial enterprise. Mitch did an exceptional job shepherding this revolutionary approach through product development, and now we are ready to establish Zeltiq as the premier technology brand in the aesthetic market," said Director Nathan Every, MD, MPH, of Frazier Healthcare Ventures.

Prior to joining Prism, Mr. Nye served as a Director, early stage investor, and CEO of REVA Medical, Inc., the developer of a novel resorbable, drug-eluting stent for the interventional cardiology market. In 1998, Mr. Nye and colleagues at Group Outcome joined with Liberty Partners to acquire Critikon, the patient monitoring unit of Johnson & Johnson. There, he served as President and CEO and led a comprehensive product line overhaul. GE Medical Systems acquired Critikon in 2000. Mr. Nye
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler
2. California Cryobank Names Richard Jennings President of FamilyCord Division
3. Association of Clinical Research Organizations (ACRO) Names Dr. Derek Winstanly Chair-Elect
4. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
5. Xytis Names Gordon H. Busenbark as Chief Financial Officer
6. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
7. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
8. Dr. Derek Winstanly of Quintiles to Serve as 2009 ACRO Chair; Mr. William Sharbaugh of PPD to Be Chair-Elect
9. Photos: SOS Childrens Villages Observes World Orphan Week, October 5-11, 2008
10. BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial
11. Snapshots of Eyes Could Serve as Early Warning of Diabetes or Diabetic Eye Disease, U-M Researchers Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Public/Private Sector Strategies for America,s Health Care Future (PS2) ... its report detailing how the state can reduce its ... areas that conservatively would save Florida taxpayers up to ... to identify steps the state could take that would ...
... EXTON, Pa., March 29, 2011 ViroPharma Incorporated (Nasdaq: ... Phase 2 clinical study to evaluate the safety and ... of acute antibody-mediated rejection (AMR) in recipients of donor-specific ... double blind, placebo-controlled study will evaluate the safety, tolerability ...
Cached Medicine Technology:Senate Receives Rx Blueprint Plan That Reduces Spending and Increases Quality 2ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR) 2ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR) 3ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR) 4ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR) 5
(Date:4/24/2014)... New research led by a scientist at the University ... key element in the development of the nervous system ... of breast cancer., A research team, led by ... the Department of Biology at York, has studied how ... tumours. These channels are found in the membranes of ...
(Date:4/23/2014)... April 24, 2014 Pregnant immigrants from Sub-Saharan ... increased monitoring during pregnancy, according to new research ... today in the British Journal of Obstetrics ... and eclampsia rates among immigrants and native-born women ... (Ontario), Denmark, Sweden, Spain (Catalonia and Valencia) and ...
(Date:4/23/2014)... O,Shea, M.D., scientific director at the National Institute of ... named the 2014 recipient of the Ross Prize in ... journal Molecular Medicine . The award will be ... of Sciences in Manhattan, followed by scientific presentations by ... of the National Institutes of Health. , The award, ...
(Date:4/23/2014)... Johns Hopkins scientists report that rats exposed to high-energy ... deep space mission, show lapses in attention and slower ... extremely low dose ranges. , The cognitive impairments ... of the animals appear to be linked to ... findings, if found to hold true in humans, suggest ...
(Date:4/23/2014)... compound that targets an important brain receptor has a ... including relapse behavior, a University at Buffalo animal study ... this may be a novel lead compound for treating ... UB research was published as an online preview article ... study, the compound, RO5263397, severely blunted a broad range ...
Breaking Medicine News(10 mins):Health News:Breast cancer replicates brain development process 2Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2
... she made her American debut at the side ... ViKY, as she is affectionately known, is a ... France. With ViKY at his side, Dr. Rosenfield ... laparoscopic hysterectomy in the world. Significantly, the entire ...
... surgery for athletes greatly reduces risk of recurring injury, ... -- Surgery to repair a young athlete,s dislocated shoulder ... to experts who looked at two types of shoulder ... , "Studies show that performing arthroscopic surgery to repair ...
... 2 GAC International ( www.gacintl.com ) announced today ... Mystique(R) MB. This second generation ceramic bracket ... system into the design, ensuring reliable bonding and debonding ... number of teens and adults seeking aesthetic treatment, now ...
... a special MRI technique, researchers have determined that the location ... sufferers can be markedly persistent over time. The findings will ... , "A considerable number of airways appeared to be ... E. de Lange, M.D., professor of radiology at the University ...
... first hip replacement fails, patients may be concerned that their ... the prognosis is poor. However, a research study to be ... Bone and Joint Surgery suggests that this may not ... Center examined their results using one of the first cementless ...
... of Salmonella , there are many questions. And answers ... start? Can it be contained? Is the sickness likely to ... for testing for the presence of Salmonella that ... by Byron Brehm-Stecher, assistant professor in food science and human ...
Cached Medicine News:Health News:A World First in Minimally Invasive Robotic Surgery Promises a More Cost-Effective, Patiently Friendly Future 2Health News:A World First in Minimally Invasive Robotic Surgery Promises a More Cost-Effective, Patiently Friendly Future 3Health News:Quick Orthopedic Repair Can Save Young Shoulders 2Health News:GAC International Launches Mystique(R) MB Second Generation Ceramic Bracket 2Health News:Even with medication, asthma patients show chronic airflow changes in lungs 2Health News:Cementless cup device developed for hip replacements shows durability after more than 20 years 2Health News:ISU researchers develop technique for quick detection of Salmonella 2
Manufacturer of the WellPro since 1992, ProGroup previously distributed the instrument through Denley and Labsystems. A direct replacement for the ProPette the WellPro performs serial dilutions in an...
... compatible with hood installations. ... system for 384-well plates, ... prepares large quantities of ... Wellpro also performs plate ...
... The Aquarius 384 is a ... Aquarius 384-well head is a unique ... washing using the included wash system. ... 250 microplate stacker system. Will ...
... new Nanopipetting System Genesis NPS based on ... allows you to miniaturize your assays for ... picking and direct dilutions., Furthermore it ... applications including gene expression analysis, gene mapping, ...
Medicine Products: